Biotechnology companies hold some of the world's most valuable intellectual property — genomic sequences, clinical trial data, and proprietary molecular formulations — that nation-state actors actively target through supply-chain infiltration and research network compromise. Zero Trust architecture protects biotech R&D environments by enforcing researcher identity verification, data-access logging, and partner network isolation under frameworks including HIPAA (for clinical data), GDPR (for EU subject genomic data), and 21 CFR Part 11 for FDA-regulated laboratory systems.
Related: Pharma · HIPAA · GDPR · LIMS · Healthcare